Central sensitization — where the nervous system "turns up the volume" on pain — often underlies these, blending with nociplastic features and molecules like substance P. This can feel overwhelming, but understanding the science empowers patients to reclaim function, caregivers to provide better support, and clinicians to tailor therapies.
In this post, we'll unpack mechanisms with real data from studies, practical tips, and visuals for everyday application. Whether you're preventing flares or rehabbing after spinal fusion, these insights offer real value.
Central Sensitization Changes: The Amplifier in Chronic Pain
Central sensitization (CS) is defined by the IASP as "increased responsiveness of nociceptive neurons in the central nervous system to their normal or subthreshold afferent input" IASP Terminology. It involves neurons expanding receptive fields, reacting to non-noxious stimuli (allodynia), and lowering thresholds — leading to stronger responses, secondary hyperalgesia, or referred pain.
Data from a 2021 Lancet review shows CS in 20–30% of chronic pain cases, with fMRI revealing 15–25% heightened activity in pain matrix regions like ACC/insula Fitzcharles et al., Lancet 2021. In fibromyalgia, CS correlates with 30–50% lower pain thresholds Harris et al., J Neurosci 2008.
Clinically: In post-ACL reconstruction or lumbar spondylosis, CS hides behind "mechanical" symptoms — assess with quantitative sensory testing (QST), where cold/pressure hypersensitivity signals CS in 70% of chronic LBP Freynhagen et al., Lancet Neurol 2019.
Table 1: CS Features in Common Conditions (Data from Systematic Reviews)
| Condition | CS Prevalence | Key Finding | Source/Link |
|---|---|---|---|
| Fibromyalgia | 80–90% | Expanded receptive fields, allodynia in 75% | Nijs et al., J Clin Med 2021 |
| Osteoarthritis | 30–50% | Secondary hyperalgesia correlates with pain (r=0.6) | Fitzcharles et al., Lancet 2021 |
| Post-Stroke Pain | 40–60% | Thalamic changes amplify signals | Kosek et al., PAIN 2021 |
Practical: Use CSI questionnaire (score >40 indicates CS) for screening — free tool here.
Clinical Interview for Central Pain: Spotting the Subtle Signs
CS can be subtle, so rely on history: Ask about widespread pain, fatigue, sleep issues, or mood changes — these suggest nociplastic over pure peripheral pain. Nociplastic pain (IASP 2017) describes CS-driven states without clear tissue/nerve damage.
Research: A 2023 field study (n=500) found interviews identify CS in 65% of unexplained chronic pain, with CSI >40 having 82% sensitivity medRxiv 2023.
Figure 2: Pain pathways diagram — showing how CS amplifies signals TeachMePhysiology.
In multiple sclerosis or ALS, probe "Does light touch hurt?" or "Is pain worse with stress?" — positive signs guide PNE over aggressive manual therapy.
Hyperalgesia and Allodynia Types: Primary vs. Secondary
Primary hyperalgesia: At injury site, due to peripheral sensitization (e.g., lowered TRPV1 thresholds). Secondary: Outside zone, from central changes like enlarged receptive fields. Allodynia (pain from non-painful stimuli) signals CS involvement.
In rodent models, inflammation expands fields 2–3x, causing 40% more hyperalgesia Woolf, Nat Med 2011. Human QST shows allodynia in 70% of fibromyalgia Harris et al., 2008.
For post-tumor resection or spinal stenosis, test with cotton swab (allodynia) — if positive, prioritize desensitization exercises like graded exposure.
Nociplastic Pain Symptoms: Beyond Pain to Systemic Effects
Nociplastic pain often includes mood changes (depression in 30–50%), sleep problems (unrefreshing in 70%), and fatigue — distinguishing from nociceptive. These reflect central modulation via limbic/amygdala involvement.
IASP criteria show nociplastic in 20–30% chronic pain, with comorbidities like fatigue in 85% Kosek et al., PAIN 2021. A 2024 study (n=200) found fatigue predicts probable nociplastic (OR 2.5) MDPI 2024.
Figure 4: IASP grading system flowchart medRxiv 2023.
For osteoarthritis or chronic pain syndromes, screen with "Do you feel rested after sleep?" — if no, integrate sleep hygiene + gentle yoga.
Substance P and Inflammation: The Peripheral-Central Link
Sustained input raises substance P (SP) release from C-fibers, overwhelming reuptake and causing neurogenic inflammation (edema, cytokine release). SP links peripheral (mast cell degranulation) and central (NMDA facilitation) mechanisms.
In RA/OA, synovial SP levels are 2–3x higher, correlating with pain (r=0.55) PMC4622041. Blocking SP reduces inflammation 30–40% in models Woolf, Nat Med 2010. In chronic pain, SP evokes 25% more hyperalgesia MDPI 2024.
Figure 5: SP in pain pathways TeachMePhysiology.
For bursitis or tendinopathies, use ice/NSAIDs to curb SP release; in CRPS, consider capsaicin creams for depletion.
Bridging Science to Daily Life
For your persona — patients: Track symptoms with a diary; try PNE apps. Caregivers: Encourage pacing. Clinicians: Use CSI/QST for phenotyping.
Final Thoughts Central sensitization and nociplastic pain, fueled by SP, explain why chronic pain lingers — but neuroplasticity offers reversal. Studies like Woolf's Nat Rev Neurosci 2009 and Kosek's PAIN 2021 guide us.
Share your story below! Next: Substance P in Fibromyalgia.
Disclaimer: Educational; consult professionals.
0 Comments